



Features and prognostic impact of distant metastases in 44 dogs with de novo stage IV cutaneous mast cell tumors: a prospective study

Journal:	<i>Veterinary and Comparative Oncology</i>
Manuscript ID	Draft
Manuscript Type:	Original Article
Keywords:	mast cell tumor, metastases, stage IV, dog, outcome

SCHOLARONE™
Manuscripts

Review Only

1
2
3 **Features and prognostic impact of distant metastases in 44 dogs with de novo**
4
5 **stage IV cutaneous mast cell tumors: a prospective study**
6
7
8
9

10
11 **Pizzoni S,¹ Sabattini S,² Stefanello D,³ Dentini A,⁴ Ferrari R,³ Dacasto M,⁵ Giantin**
12 **M,⁵ Laganga P,¹ Amati M,⁶ Tortorella G,⁷ Marconato L¹**
13
14
15
16
17
18
19

20
21 1 Centro Oncologico Veterinario, Sasso Marconi, Italy

22
23 2 Department of Veterinary Medical Sciences, University of Bologna, Italy

24
25 3 Department of Veterinary Medicine, University of Milan, Italy

26
27 4 Clinica Tyrus, Terni, Italy

28
29 5 Department of Comparative Biomedicine and Food Science, University of Padua,
30
31 Legnaro, Italy

32
33 6 Ospedale Veterinario Città di Pavia, Pavia, Italy

34
35 7 Laboratorio La Vallonea, Alessano, Lecce, Italy

36
37
38
39
40
41
42
43 *** Corresponding author:**

44
45 Laura Marconato, DVM, DECVIM-CA (Oncology)

46
47 Centro Oncologico Veterinario

48
49 Via San Lorenzo 1/4

50
51 40037 Sasso Marconi, Italy

52
53 marconato@centroncologicovet.it
54
55
56
57
58
59
60

1
2
3 **Abbreviated title**
4

5 Canine stage IV cutaneous mast cell tumors
6
7

8
9 **Keywords**
10

11 Mast cell tumor, metastases, stage IV, dog, outcome
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Abstract

Distant metastases in dogs with cutaneous mast cell tumors (cMCT) are rare and incurable. The clinico-pathological features of 44 stage IV cMCT dogs were prospectively investigated in relation to outcome. Dogs were uniformly staged and followed-up, whereas treatment was not standardized. Median survival time (ST) was 125 days. Notably, progression-free survival and ST were independent of well-known prognostic factors, including anatomic site, histological grade, and mutational status. Conversely, tumor diameter >3 cm, more than 2 metastatic sites, bone marrow infiltration, and lack of tumor control at the primary site were confirmed to be negative prognostic factors by multivariate analysis. Currently, the treatment effectiveness for stage IV cMCT is not ideal. Asymptomatic dogs with tumor diameter <3 cm and a low tumor burden, without bone marrow infiltration may be candidates for multimodal treatment. The achievement of local tumor control seems to predict a better outcome in dogs with stage IV cMCT.

Introduction

In dogs, cutaneous mast cell tumor (cMCTs) is a clinically heterogeneous disease. Cutaneous MCTs may have a low malignant potential or be extremely aggressive, showing local invasiveness and a high metastatic risk.¹ The most important independent prognostic factors are histological grading (according to Patnaik and Kiupel grading systems) and clinical stage, as they predict the biological behavior and provide reliable therapeutic indication.²

The vast majority of the clinical concerns of oncologists are related to the treatment of metastases, including how to eradicate, shrink or palliate the complications of metastatic disease.

A significant improvement in the locoregional control of cMCT has been seen over the last decades thanks to the advent of new antitumoral strategies and improved understanding of the biology of the disease. However, this improvement does not seem to have significantly influenced the final survival rate in the case of de novo stage IV disease, a relatively rare but clinically relevant event.²⁻⁴

The clinical relevance of nodal metastasis has been intensively explored, resulting in a poorer clinical outcome according to several studies.⁵⁻⁷ Particularly, histological rather than cytological LN staging is of crucial importance for prognosis estimation and therapy stratification, as it is one of the strongest prognostic parameter in curative cases.^{2,5} In node-positive cMCT, systemic chemotherapy and/or tyrosine kinase inhibitors (TKIs) is generally recommended. In contrast, the benefit in stage I cMCTs is minimal, and the decision of whether to use medical therapy depends on additional risk factors. Based on the above, the regional lymph node (LN) should always be assessed to determine the accurate stage of disease.⁸

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conversely, the clinical value of distant metastases in cMCT has been investigated only in a few studies.^{3,4} Recently it has been documented that approximately 5% of dogs with cMCT are diagnosed with distant metastases at initial presentation,² yet their prognostic relevance has not been intensively explored, as their disease is considered incurable, leading to palliative treatments and/or early euthanasia in the majority of cases. Indeed, current information on the prognostic value of distant metastases is largely dependent on retrospective series that have been collected during several years and at multiple institutions.^{3,4,9} Staging procedures as well as molecular analysis underwent a substantial change in recent years, leading to the need of reconsidering the relevance of new findings for dogs with metastatic disease.

The aims of this prospective study were to clarify the features of distant metastases of WHO stage IV cMCTs and to identify the prognostic factors for these dogs.

Material and methods

Inclusion criteria

Members of the Italian Society of Veterinary Oncology (SIONCOV) were asked to participate to this prospective, multi-institutional study. Dogs were eligible for recruitment if they had a previously untreated, histologically confirmed cMCT and if they underwent complete staging demonstrating stage IV disease.

Background information recorded for each dog included signalment, body weight, primary tumor description (anatomic location, largest diameter, grade according to the systems of Patnaik and Kiupel, *c-kit* mutational status),¹⁰⁻¹² clinical stage and

1
2
3 substage; site of metastasis; date of surgery or incisional biopsy; other adjuvant
4
5 treatments; response of the primary tumor to treatment; response of the metastatic
6
7 sites to treatment; date of death or last follow-up examination; cause of death; and
8
9 occurrence of treatment-related toxicity.

10
11 Initial staging included history and physical examination, complete blood cell count
12
13 with differential, serum biochemistry, coagulation profile, histological examination of
14
15 the cutaneous nodule, histological or cytological examination of regional LN, thoracic
16
17 radiographs (3 views) and abdominal ultrasound examination or total body computed
18
19 tomography (TBCT), fine-needle aspirates of liver and spleen regardless of their
20
21 sonographic appearance, and cytologic examination of BM obtained from the iliac
22
23 crest.
24
25

26
27 The regional LN was defined as the first LN in the expected lymphatic drainage, and
28
29 was identified either by palpation or by means of ultrasound. Cytologically, LNs or
30
31 viscera were considered metastatic, if mast cells appeared in clusters or sheets, in
32
33 very large numbers or atypical on morphology, as previously documented.³
34
35 Histologically, LNs were considered metastatic in the presence of aggregates of mast
36
37 cells in sinuses (subcapsular, paracortical or medullary) or parenchyma. Giemsa stain
38
39 was applied in the uncertain cases. Bone marrow (BM) was considered infiltrated if
40
41 mast cells were more than 10% of all nucleated cell, or, if atypical, more than 5 % of all
42
43 nucleated cell, as previously described.⁹
44
45

46
47 Written informed consent was obtained from all owners.
48
49

50 51 52 **Treatment and response**

53
54 The type of treatment was at the investigator's personal discretion, and included no
55
56 therapy, surgery, radiation therapy, chemotherapy, TKI or a combination of these.
57
58 Depending on treatment, dogs were re-assessed as follows: on a weekly basis if
59
60

1
2
3 vinblastine was administered, on a monthly basis if lomustine, TKI or no treatment was
4 administered. Physical examination, fine-needle aspiration of any new lesion, and
5 bloodwork were routine elements of each assessment. An abdominal ultrasound was
6 repeated every 1-2 months. All responses were defined according to the RECIST
7 criteria.¹³ Response was confirmed at least 4 weeks (for complete remission, CR, or
8 partial remission, PR) or 6 weeks (for stable disease, SD) after the first documentation.
9
10 Local tumor control was defined as objective local tumor response in addition to
11 freedom from local progression. Distant tumor control was defined as objective distant
12 tumor response in addition to freedom from distant progression.
13
14
15
16
17
18
19
20
21
22
23
24

25 **Statistical analysis**

26
27 Progression free interval (PFI) was calculated from the date of stage IV diagnosis to
28 the date of loco-regional and/or distant tumor progression. Survival time (ST) was
29 calculated from the date of stage IV diagnosis to the date of last visit or death. Dogs
30 lost to follow-up or dead due to MCT-unrelated causes were right-censored at the last
31 date of known status or at the date of death, respectively.
32
33
34
35
36
37

38 The following factors were investigated for prognostic significance: age, sex, weight,
39 anatomic location of primary tumor, primary tumor diameter, regional LN metastasis,
40 number of metastatic sites, BM infiltration, substage, histopathological grade (Patnaik
41 and Kiupel), *c-kit* mutational status, measurable primary tumor, type of treatment
42 (surgery vs radiation therapy vs medical treatment), type of medical treatment
43 (chemotherapy vs TKI), treatment-related toxicity, local and distant tumor control.
44
45
46
47
48
49
50

51 The influence of these factors on PFI and ST was investigated with a univariate Cox
52 regression analysis. Median PFI and ST were assessed by means of the Kaplan-Meier
53 survival curves. Factors that on univariate analysis had a P value < 0.05 were further
54 tested for independence in a multivariate Cox proportional hazard model.
55
56
57
58
59
60

1
2
3 Statistical analysis was performed with SPSS Statistics v.19 (IBM, Somers, NY, USA).
4
5 Significance was set at $P < 0.05$.
6
7
8
9

10 11 **Results**

12 13 ***Dogs and MCT Demographics***

14
15
16 Between 2011 and 2016, 44 dogs matched the inclusion criteria and were enrolled.

17
18 There were 16 (36.4%) mixed breed dogs, 7 (15.9%) Labrador Retrievers, 4 (9.1%)
19
20 Boxers, 3 (6.8%) French Bouledogue, 2 (4.5%) Yorkshire terrier, 2 (4.5%) Maltese,
21
22 and one (2.3%) each of the following: Shih-Tzu, Beagle, American Staffordshire terrier,
23
24 Dobermann, Pinscher, Argentine Mastiff, Bullmastiff, Pitbull terrier, Boston terrier, and
25
26 Malinois. Twenty-three (52.3%) dogs were female (14 spayed), and 21 (47.7%) were
27
28 male (5 castrated). Median age was 9 years (range, 2 to 14 years), and median weight
29
30 was 25.2 kg (range, 2.5 to 47.5 kg).
31
32
33
34
35

36 Mast cell tumors were in various locations, including 11 (25%) dogs with MCTs on
37
38 head and neck, 10 (22.7%) dogs with tumors on proximal limbs (above elbow/ knee), 6
39
40 (13.6%) dogs with MCTs on the thoracic wall, 3 (6.8%) dogs with digital tumors, 3
41
42 (6.8%) dogs with mammary MCTs, 3 (6.8%) dogs with tumors on the scrotum, 2
43
44 (4.5%) dogs with MCTs on the abdominal wall, 2 (4.5%) dogs with axillary MCTs, 2
45
46 (4.5%) dogs with tumors on the prepuce, 1 dog (2.3%) with MCT on the vulva and 1
47
48 dog (2.3%) with MCT on distal limb (distal to knee/ elbow).
49
50

51 Median tumor diameter was 3.15 cm (range, 0.3 to 20 cm).
52

53
54 Twenty-six (59.1%) dogs were asymptomatic (substage a), whereas 18 (40.9%) dogs
55
56 showed clinical signs and symptoms at diagnosis of stage IV disease (substage b),
57
58
59
60

1
2
3 including vomiting, diarrhea, localized and/or generalized pruritus, and regional
4
5 edema.
6
7

8
9
10 All dogs underwent complete staging work-up, as previously described; 35 (79.5%)
11
12 dogs underwent three-view thoracic radiographs and abdominal ultrasound, whereas 9
13
14 (20.5%) dogs had a TBCT performed.
15

16 All dogs had distant metastatic disease: 22 (50%) dogs had splenic and hepatic
17
18 metastasis, 6 (13.6%) dogs had hepatic metastasis, 3 (6.8%) dogs had splenic
19
20 metastasis, 3 (6.8%) dogs had metastases in the spleen, liver and non-regional LNs, 3
21
22 (6.8%) dogs had metastases in the spleen, liver and BM, 2 (4.5%) dogs had
23
24 metastases in the spleen and BM, 1 (2.3%) had metastases in the spleen, liver, BM
25
26 and peripheral blood, 1 (2.3%) had splenic, hepatic and pulmonary metastases, 1
27
28 (2.3%) had metastases in the spleen and non-regional LNs, 1 (2.3%) had splenic,
29
30 renal and BM metastases, and 1 (2.3%) had metastases in the spleen, liver, BM, and
31
32 non-regional LNs.
33
34

35
36 Forty (90.9%) dogs had also metastasis in the regional LN, while 4 (9.1%) dogs did
37
38 not. Lymph node metastases were confirmed in 30 (68.2%) dogs by means of
39
40 histopathology, whereas the remaining 10 (22.7%) dogs had only a cytologic
41
42 diagnosis. Regarding the 4 dogs without LN metastasis, the diagnosis was by means
43
44 of histopathology in 3 (75%) of them, and by means of cytology in 1 (25%) dog.
45
46 Visceral metastases were confirmed in all cases by means of cytology.
47
48
49

50
51 Histopathology was available for all primary cMCTs: 22 (50%) dogs had Patnaik's
52
53 grade 2 cMCTs, 20 (45.5%) dogs had grade 3 MCTs, and 2 (4.5%) dogs had grade 1
54
55 cMCTs. Regarding the Kiupel's grading system, 28 (63.6%) tumors were classified as
56
57 high grade cMCTs, and 16 (36.4%) as low grade cMCTs.
58
59
60

1
2
3
4
5 Tissue specimens of all dogs were suitable for *c-kit* genotyping.
6

7 Internal tandem duplications were detected in 13 (29.5%) cMCTs: 8 in exon 11, 4 in
8 exons 11 and 12, and 1 in exon 8. Nine (20.5%) silent single nucleotide
9 polymorphisms (SNPs) were detected in exon 8, and 1 (2.3%) silent SNP in exon 11.
10
11 Twenty-one (47.7%) dogs had wild type (WT) genotype (exons 8, 9, 11, and 12).
12
13
14
15

16 17 18 ***Treatment and clinical follow-up*** 19

20 Surgery was the primary treatment for 31 (70.5%) dogs; in 18 of them the MCT
21 recurred shortly (within 30 days) postoperatively and those dogs had consequently
22 macroscopic disease when first referred. Twenty-eight of the 31 dogs also received
23 systemic treatment postoperatively, while 2 of 31 dogs also received curative-intent
24 radiation therapy. Curative-intent radiation therapy ranged from 14 to 16 fractions for a
25 total dose of 45 to 48 Gy.
26
27
28
29
30
31
32

33 Ten (22.7%) of 44 dogs only received medical treatment as primary therapy.
34

35 Three (6.8%) of 44 dogs received a combination of palliative radiation therapy and
36 systemic treatment as primary therapy. Palliative radiation therapy consisted of 5
37 fractions of 6 to 8 Gy each.
38
39
40
41

42 Overall, 41 (93.2%) dogs received systemic therapy, consisting of TKIs (n=21), dose-
43 intense chemotherapy (n=7), or a combination of these (n=13).
44

45 Twelve (31.6%) out of the 38 dogs receiving medical treatment experienced treatment-
46 related toxicity, consisting of grade 1 lethargy (n=1), grade 1 (n=2), 2 (n=2) and 3
47 (n=1) gastro-intestinal side effects, grade 1 (n=1), 2 (n=1) and 3 (n=2) hematologic
48 toxicity, and grade 2 hepatotoxicity (n=2).
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 When evaluating the primary MCT, 31 (70.5%) dogs had measurable disease and
4 were therefore assessable for antitumor response. Three (9.7%) dogs achieved CR,
5
6
7 12 (38.7%) dogs experienced PR, in 4 (12.9%) dogs the primary disease was stable,
8
9
10 whereas in 12 (38.7%) dogs was progressive, for an overall response rate in the
11
12 macroscopic setting of 48.4%.

13
14 When considering metastatic disease in this group of dogs (including nodal and
15
16 visceral), 3 (9.7%) dogs achieved CR at their metastatic sites, 2 (6.5%) dogs achieved
17
18 PR, 6 (19.4%) dogs obtained SD, and 20 (64.5%) dogs progressed. Complete
19
20 response was documented by imaging and confirmative cytology.
21
22

23
24
25 None of the 13 (29.5%) dogs with surgically removed cMCT progressed at the primary
26
27 site during the study period.
28

29
30 When considering metastatic disease in this group of dogs (including nodal and
31
32 visceral), 4 (30.8%) dogs obtained CR, 4 (30.8%) dogs obtained PR, 4 (30.8%) dogs
33
34 were stable, and 1 (7.7%) dog progressed. Overall, median PFI was 45 days (95% CI,
35
36 9.4-80.6 days).
37
38

39
40 The median follow-up time was 306 days (range, 16 to 1246 days). Thirty-nine (88.6%)
41
42 dogs died or were euthanized within the follow-up period; among them, 38 died
43
44 because of MCT-related disease and 1 because of a brain tumor after 380 days. Five
45
46 (11.4%) dogs were alive at the end of the study. Overall, median ST was 125 days
47
48 (95% CI, 84.8 to 165.2 days).
49
50

51 52 53 54 ***Analysis of prognostic factors*** 55 56 57 58 59 60

1
2
3 In univariate analysis, factors significantly associated with PFI were: tumor diameter
4 >3 cm, more than 2 metastatic sites, substage b, and measurable primary tumor
5 (Table 1).
6
7

8
9 Factors significantly associated with ST were: tumor diameter >3 cm, regional LN
10 metastases, more than 2 metastatic sites, BM infiltration, substage b, and lack of local
11 and distant tumor control (Table 2).
12
13

14
15 In multivariate analysis, tumor diameter >3 cm, more than 2 metastatic sites and
16 measurable primary tumor at diagnosis of stage IV disease were still significantly
17 associated with PFI, whereas the factors associated with ST were BM infiltration and
18 lack of local tumor control (Tables 3 and 4).
19
20
21
22
23

24 Age, sex, weight, anatomic location of the primary tumor, histopathological grade,
25 mutational status, type of treatment, and onset of treatment-related toxicity were not
26 significantly associated with either PFI or ST.
27
28
29
30
31
32
33
34
35

36 Discussion

37
38
39
40 Approximately 5% of dogs with cMCT have distant metastasis at initial diagnosis, with
41 liver, spleen, BM and distant LNs being the major sites of metastatic involvement.²
42

43 Distant metastases are for most solid tumors decisive life-threatening events. Up to
44 date, based on the recent literature, stage IV cMCT is perceived to be a very
45 aggressive and ominous disease carrying a poor prognosis, with reported survival
46 times ranging from 34 to 100 days among a total of 31 dogs examined in 3 studies.^{3,4,9}
47
48

49 Due to its incurability, many veterinary oncologists do not advice to pursue any
50 oncologic treatment, and rather euthanasia is suggested or even carried out right after
51
52
53
54
55
56
57
58
59
60

1
2
3 staging results. Moreover, potential chemotherapy-related toxicity leads owners to opt
4
5 out of medical oncologic treatment for their dogs.⁹
6

7
8 Unfortunately, the studies published so far have only marginally improved the
9
10 understanding of the outcome of dogs with stage IV disease, as no systematic body of
11
12 knowledge on the clinical features, diagnosis, or treatment of such cases is available.
13
14 Importantly, there are no guidelines on how to manage dogs presenting with stage IV
15
16 cMCT, and decisions are often left to provider and owner preferences.
17

18
19 To our knowledge, this is the largest case series of dogs with de novo stage IV cMCT
20
21 enrolled prospectively, uniformly staged and followed-up.
22
23

24
25 In this study, dog characteristics were similar to previous publications with median age
26
27 of diagnosis of 9 years and no sex predilection.⁸ In agreement with the literature,
28
29 Labrador retrievers were over-represented.¹⁴ While Boxers have been described to
30
31 carry a better prognosis,^{1,8,10} in the current study this breed was slightly over-
32
33 represented, suggesting that the biologic behavior cannot be entirely anticipated by
34
35 the signalment.
36
37

38
39 The same holds true for anatomic site of primary tumor development. While 23 of 44
40
41 dogs (52.3%) had MCTs that developed in sites described to behave in a more
42
43 malignant fashion,⁸ 21 (47.7%) did not.
44

45
46 Of utmost importance is the variability of grading that was documented in this series of
47
48 dogs. Twenty-two (50%) dogs had Patnaik grade 1 and 2 cMCTs, and 16 (36.4%) had
49
50 Kiupel low-grade cMCTs, thereby limiting the utility of histologic evaluation as the sole
51
52 predictor of outcome.² In addition, the statistical evaluation confirmed the non-
53
54 prognostic role of histological grade in the presence of verified metastatic disease,
55
56 leading to hypothesize that the histopathological evaluation might not be so essential
57
58 for stage IV disease.
59
60

1
2
3 It has been reported that cMCTs harboring *c-kit* mutations, particularly some ITDs,
4 have a poorer prognosis compared to those with WT *c-kit* genes.¹⁵⁻¹⁷ Mutational status
5 was documented in all dogs, and surprisingly 21 (47.7%) dogs had WT genotyping
6 (exons 8, 9, 11, and 12).
7
8

9
10
11 As a whole, these data suggest that multiple variables need to be taken into
12 consideration when predicting the biological behavior of cMCTs, with complete staging
13 work-up being fundamental.
14
15
16

17
18
19
20 Our clinical data confirm the poor outcome of stage IV disease, with a median ST of
21 125 days. Nevertheless, based on our results, the diagnosis of distant metastatic
22 disease is not always necessarily a death sentence, as selected dogs may enjoy
23 prolonged survival, clearly suggesting that additional factors in concert need to be
24 taken into account to define prognosis.
25
26
27

28
29
30 Indeed, the current study identified some prognostic indicators in dogs with stage IV
31 cMCT. Surprisingly, while the PFI and ST for this group of dogs were largely
32 independent of well-known prognostic factors, such as anatomic site, histological
33 grade, and mutational status,^{10,11,15,19,20} some reported negative prognostic factors
34 were confirmed.
35
36
37

38
39
40 That presence of systemic symptoms is associated with outcome has been already
41 verified.^{8,21} In our study, substage was an indicator of PFI and ST by univariate
42 analysis; however, this relationship was not confirmed by multivariate analysis.
43
44

45
46
47 In agreement with previous studies, dogs with cMCTs larger than 3 cm had a
48 significantly shorter PFI and ST.^{2,21,22} The relationship with PFI was confirmed as
49 independent factor by multivariate analysis. Accordingly, the presence of measurable
50 primary MCT at diagnosis of stage IV disease was associated with significantly
51
52
53
54
55
56
57
58
59
60

1
2
3 shorter PFI by multivariate analysis. In 18 of these 31 dogs, the measurable tumor
4 represented recurrent disease shortly after a first surgery. As a whole, these results
5 show that bulky disease may not be amenable to efficient local treatment, thereby
6
7
8
9
10 worsening prognosis.

11
12
13
14 Metastatic burden also had a negative influence on PFI and ST according to
15 univariate analysis, with more than 2 metastatic sites being associated with a poor
16
17
18
19
20
21
22 outcome, but was not confirmed as independent factor for ST by multivariate
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
analysis.

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204

1
2
3 progression in cancer spread remains to be defined, but according to our results it
4
5 may be possible that a small percentage of cMCT has different mechanisms of
6
7 disease spread.
8
9

10
11 As already documented,⁹ BM infiltration has important biologic implications, and was
12
13 significantly associated with shorter ST by multivariate analysis. Disseminated tumor
14
15 cells found in the BM may serve as reservoir of dormant cancer cells, representing
16
17 the founder cells of overt metastases.²⁶ In general, disseminated cancer cells are
18
19 considered to have a more aggressive phenotype, as they have developed the ability
20
21 to home and survive in the BM, and evade the host immune recognition at the
22
23 regional LN, being then able to colonize distant sites.²⁶ Of note, only 1 of the 8 dogs
24
25 (12.5%) with BM infiltration had concurrent circulating neoplastic cells. This is in
26
27 agreement with the human literature, showing that circulating neoplastic cells are
28
29 numerically fewer than disseminated neoplastic cells, thereby requiring extremely
30
31 sensitive analytical methods for their detection.^{27,28} As a consequence, BM should
32
33 always be part of the staging work-up in dogs with nodal and/or visceral metastasis,
34
35 as it indicates a higher tumor burden and a worse prognosis (median ST 35 days vs
36
37 146 days, with and without BM infiltration, respectively).
38
39
40
41
42
43
44

45 Lack of tumor control at the primary and distant sites was significantly associated
46
47 with ST; however only tumor control at the primary site retained significance by
48
49 multivariate analysis. The variability in outcome is in part dependent on the type of
50
51 treatment. The dogs receiving local treatment (surgery and/or radiation therapy) plus
52
53 systemic treatment (chemotherapy or TKI or both) had a better outcome than those
54
55 that did not. Similar results have been observed in a previous study,¹⁴ suggesting
56
57 that surgical resection of the primary cMCT followed by systemic therapy offers a
58
59
60

1
2
3 significant survival advantage compared to dogs receiving chemotherapy without
4
5 local control.
6
7

8
9
10 This study has some limitations. Although LN metastases were confirmed or ruled
11
12 out by means of histopathology in the majority (75%) of cases, visceral metastases
13
14 were confirmed by cytology in all cases. Nevertheless, the presence of several
15
16 aggregates of mast cells, and their atypical morphology rendered the hypothesis of
17
18 non-neoplastic mast cells unlikely in these cases.
19

20
21 Within our series, there was heterogeneity of treatment, as many owners elected not
22
23 to pursue aggressive approaches to management due to the poor prognosis.
24
25

26
27 In conclusion, stage IV cMCTs are rare and associated with a poor outcome.
28
29 Nevertheless, asymptomatic dogs with tumor diameter <3 cm and a low tumor
30
31 burden, without BM infiltration may be candidates for local treatment plus systemic
32
33 treatment. Stage IV dogs without LN metastasis may enjoy a surprisingly prolonged
34
35 survival. The achievement of local tumor control seems to be the main predictor of
36
37 better outcome in dogs with stage IV cMCT.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. London CA and Thamm DH. Mast cell tumours. In: *Withrow & MacEwen's Small Animal Oncology*. 5edn. SJ Withrow, DM Vail and Page RL Eds, Philadelphia, Saunders, 2013: 335-355.
2. Stefanello D, Buracco P, Sabattini S, Finotello R, Giudice C, Grieco V, *et al.* Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014). *Journal of the American Veterinary Medical Association* 2015; **246**: 765-769.
3. Stefanello D, Valenti P, Faverzani S, Bronzo V, Fiorbianco V, Pinto da Cunha N, *et al.* Ultrasound-guided cytology of spleen and liver: a prognostic tool in canine cutaneous mast cell tumor. *Journal of Veterinary Internal Medicine* 2009; **23**: 1051-1057.
4. Book AP, Fidel J, Wills T, Bryan J, Sellon R and Mattoon J. Correlation of ultrasound findings, liver and spleen cytology, and prognosis in the clinical staging of high metastatic risk canine mast cell tumors. *Veterinary Radiology & Ultrasound* 2011; **52**: 548-554.
5. Weishaar KM, Thamm DH, Worley DR and Kamstock DA. Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis. *Journal of Comparative Pathology* 2014; **151**: 329-338.
6. Krick EL, Billings AP, Shofer FS, Watanabe S and Sorenmo KU. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. *Veterinary and Comparative Oncology* 2009; **7**:130-138.

- 1
2
3 7. Murphy S, Sparkes AH, Blunden AS, Brearley MJ and Smith KC. Effects of stage
4 and number of tumours on prognosis of dogs with cutaneous mast cell tumours.
5
6
7 *Veterinary Record* 2006; **158**: 287-291.
- 8
9
10 8. Blackwood L, Murphy S, Buracco P, De Vos JP, De Fornel-Thibaud P,
11 Hirschberger J *et al.* European consensus document on mast cell tumours in dogs
12 and cats. *Veterinary and Comparative Oncology* 2012; **10**: e1-e29.
- 13
14
15 9. Marconato L, Bettini G, Giacoboni C, Romanelli G, Cesari A, Zatelli A *et al.*
16 Clinicopathological features and outcome for dogs with mast cell tumors and bone
17 marrow involvement. *Journal of Veterinary Internal Medicine* 2008; **22**:1001-1007.
- 18
19
20 10. Patnaik AK, Ehler WJ and MacEwen EG. Canine cutaneous mast cell tumor:
21 morphologic grading and survival time in 83 dogs. *Veterinary Pathology* 1984; **21**:
22 469-474.
- 23
24
25 11. Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac Cj *et al.* Proposal of a
26 2-tier histologic grading system for canine cutaneous mast cell tumors to more
27 accurately predict biological behavior. *Veterinary Pathology* 2011; **48**: 147-155.
- 28
29
30 12. Marconato L, Zorzan E, Giantin M, Di Palma S, Cancedda S and Dacasto M.
31 Concordance of c-kit mutational status in matched primary and metastatic
32 cutaneous canine mast cell tumors at baseline. *Journal of Veterinary Internal*
33 *Medicine* 2014; **28**: 547-553.
- 34
35
36 13. Nguyen SM, Thamm DH, Vail DM and London CA. Response evaluation criteria
37 for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group
38 (VCOG) consensus document. *Veterinary and Comparative Oncology* 2015; **13**:
39 176-183.
- 40
41
42 14. Miller RL, Van Lelyveld S, Warland J, Dobson JM and Foale RD. A retrospective
43 review of treatment and response of high-risk mast cell tumours in dogs.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 *Veterinary and Comparative Oncology*. 2014; DOI: 10.1111/vco.12116. In press.

- 1
2
3 15. Downing S, Chien MB, Kass PH, Moore PE and London CA. Prevalence and
4 importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell
5 tumors of dogs. *American Journal of Veterinary Research* 2002; **63**:1718-1723.
6
7
- 8
9 16. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH and Kiupel
10 M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell
11 tumors. *Neoplasia* 2006; **8**:104-111.
12
13
- 14
15 17. Zemke D, Yamini B and Yuzbasiyan-Gurkan V. Mutations in the iuxtamembrane
16 domain of c-KIT are associated with higher grade mast cell tumors in dogs.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33 18. White CR, Hohenhaus AE, Kelsey J and Procter-Gray E. Cutaneous MCTs:
34 associations with spay/neuter status, breed, body size, and phylogenetic cluster.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 19. Dobson JM. Breed-predispositions to cancer in pedigree dogs. *International
Scholarly Research Notice Veterinary Science* 2013; 941275.
20. Kiupel M, Webster JD, Miller RA and Kaneene JB. Impact of tumour depth, tumour
location and multiple synchronous masses on the prognosis of canine cutaneous
mast cell tumours. *Journal of Veterinary Medicine Series A* 2005; **52**: 280-286.
21. Mullins MN, Dernell WS, Withrow SJ, Ehrhart EJ, Thamm DH and Lana SE.
Evaluation of prognostic factors associated with outcome in dogs with multiple
cutaneous mast cell tumours treated with surgery with and without adjuvant
treatment: 54 cases (1998–2004). *Journal of the American Veterinary Medical
Association* 2006; **228**: 91–95.
22. Hahn KA, King GK and Carreras JK. Efficacy of radiation therapy for incompletely
resected grade-III mast cell tumors in dogs: 31 cases (1987–1998). *Journal of the
American Veterinary Medical Association* 2004; **224**: 79–82.

- 1
2
3 23. Worley DR. Incorporation of sentinel lymph node mapping in dogs with mast cell
4
5 tumours: 20 consecutive procedures. *Veterinary and Comparative Oncology* 2014;
6
7 **12**: 215-226.
8
9
10 24. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers.
11
12 *Journal of Clinical Oncology* 1994; **12**: 2229-2234.
13
14 25. Fisher B. Laboratory and clinical research in breast cancer – a personal
15
16 adventure: the David A. Karnofsky memorial lecture. *Cancer Research* 1980; **40**:
17
18 3863-3874.
19
20
21 26. Lin H, Balic M, Zheng S, Datar R and Cote RJ. Disseminated and circulating tumor
22
23 cells: Role in effective cancer management. *Critical Reviews in*
24
25 *Oncology/Hematology* 2011; **77**: 1-11.
26
27
28 27. Riethdorf, S, Wikman H, Pantel K. Review: Biological relevance of disseminated
29
30 tumor cells in cancer patients. *International Journal of Cancer*; **123**: 1991-2006.
31
32
33 28. Pantel, K, Alix-Panabières C and Riethdorf S. Cancer micrometastases. *Nature*
34
35 *Reviews Clinical Oncology* 2009; **6**: 339–351.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 – Univariate Cox regression analysis of variables potentially associated with increased risk of disease progression in 44 dogs with stage IV cutaneous mast cell tumors.

Variable	No. of dogs	Median PFI (days)	HR	95% CI	P
Age			1.25	0.66-2.38	0.489
> 9 years‡	24	81			
≤ 9 years	20	36			
Sex			1.12	0.59-2.14	0.721
female	21	36			
male	23	81			
Neutered			1.01	0.53-1.94	0.974
no	25	45			
yes	19	81			
Weight			1.38	0.72-2.65	0.330
≤ 25.2 kg‡	22	41			
> 25.2 kg	22	46			
Negative prognostic site of primary tumor			1.02	0.54-1.94	0.949
no	23	46			
yes	21	45			
Tumor diameter at presentation			2.67	1.31-5.42	0.007*
> 3 cm	21	120			
≤ 3 cm	23	35			
Node metastasis			34.04	0.91-1277.57	0.056
yes	40	42			
no	4	940			

More than 2 metastatic sites			2.84	1.22-6.61	0.016*
<i>yes</i>	32	35			
<i>no</i>	12	84			
Bone marrow infiltration			1.52	0.62-3.75	0.359
<i>yes</i>	8	29			
<i>no</i>	36	45			
Substage			2.16	1.05-4.43	0.036*
<i>b</i>	18	41			
<i>a</i>	26	70			
Patnaik grade			1.48	0.76-2.89	0.251
3	20	46			
1, 2	24	41			
Kiupel grade			1.23	0.62-2.42	0.553
<i>high grade</i>	28	46			
<i>low grade</i>	16	36			
c-Kit mutations			1.02	0.52-1.97	0.961
<i>yes</i>	15	45			
<i>no</i>	29	46			
Measurable primary tumor at diagnosis of stage IV disease			2.77	1.28-5.95	0.009*
<i>yes</i>	31	29			
<i>no</i>	13	125			
Surgery			1.02	0.51-2.03	0.951
<i>no</i>	13	41			
<i>yes</i>	31	46			

Radiation therapy			1.14	0.44-2.96	0.782
<i>no</i>	39	45			
<i>yes</i>	5	120			
Medical treatment			1.47	0.45-4.82	0.528
<i>no</i>	3	21			
<i>yes</i>	41	46			
Type of medical treatment			1.13	0.53-2.41	0.709
<i>TKI only</i>	7	41			
<i>chemotherapy only</i>	21	42			
<i>chemotherapy and TKI</i>	13	90			
Use of TKIs in the presence of c-Kit mutations			1.17	0.59-2.33	0.655
<i>yes</i>	13	45			
<i>no</i>	31	46			
Treatment toxicity			1.01	0.50-2.03	0.972
<i>yes</i>	13	87			
<i>no</i>	31	42			

PFI = progression free interval; HR = hazard ratio; CI = confidence interval; TKI = tyrosine

kinase inhibitor; ‡ = median value; * = significant.

Table 2 – Univariate Cox regression analysis of variables potentially associated with increased risk of tumor-related death in 44 dogs with stage IV cutaneous mast cell tumors.

Variable	No. of dogs	Median OS (days)	HR	95% CI	P
Age			1.00	0.52-1.92	0.994
> 9 years‡	20	109			
≤ 9 years	24	146			
Sex			1.08	0.57-2.05	0.816
female	23	110			
male	21	146			
Neutered			1.06	0.55-2.03	0.872
no	25	101			
yes	19	146			
Weight			1.60	0.83-3.09	0.163
≤ 25.2 kg‡	22	109			
> 25.2 kg	22	133			
Negative prognostic site of primary tumor			1.24	0.65-2.34	0.512
yes	13	109			
no	31	146			
Tumor diameter at presentation			2.25	1.16-4.36	0.016*
> 3 cm	23	77			
≤ 3 cm	21	209			
Node metastasis			40.15	1.09-1477.26	0.045*
yes	40	109			
no	4	940			

More than 2 metastatic sites			3,21	1.38-7.48	0.007*
<i>yes</i>	32	77			
<i>no</i>	12	198			
Bone marrow infiltration			3.56	1.45-8.76	0.006*
<i>yes</i>	8	35			
<i>no</i>	36	146			
Substage			2.95	1.45-6.00	0.003*
<i>b</i>	18	72			
<i>a</i>	26	180			
Patnaik grade			1.50	0.78-2.91	0.226
3	20	77			
1, 2	24	150			
Kiupel grade			1.34	0.68-2.64	0.399
<i>high grade</i>	28	101			
<i>low grade</i>	16	154			
c-Kit mutations			1.19	0.61-2.31	0.604
<i>yes</i>	15	77			
<i>no</i>	29	133			
Measurable primary tumor at diagnosis of stage IV disease			1.79	0.86-3.75	0.120
<i>yes</i>	31	110			
<i>no</i>	13	180			
Surgery			1.06	0.52-2.15	0.870
<i>yes</i>	31	109			
<i>no</i>	13	146			

Radiation therapy			1.22	0.47-3.15	0.688
<i>no</i>	39	109			
<i>yes</i>	5	209			
Medical treatment			1.48	0.35-6.19	0.591
<i>yes</i>	41	110			
<i>no</i>	3	180			
Type of medical treatment			1.11	0.52-2.35	0.688
<i>TKI only</i>	7	154			
<i>chemotherapy only</i>	21	109			
<i>chemotherapy and TKI</i>	13	146			
Use of TKIs in the presence of c-Kit mutations			1.39	0.70-2.79	0.347
<i>yes</i>	13	77			
<i>no</i>	31	133			
Treatment toxicity			1.12	0.55-2.29	0.750
<i>yes</i>	13	133			
<i>no</i>	31	125			
Local tumor control			5.37	2.40-12.01	<0.001*
<i>no</i>	12	28			
<i>yes</i>	32	180			
Distant tumor control			2.68	1.38-5.23	0.004*
<i>no</i>	21	32			
<i>yes</i>	23	180			

OS = overall survival; HR = hazard ratio; CI = confidence interval; TKI = tyrosine kinase

inhibitor; ‡ = median value; * = significant.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Table 3. Multivariate Cox regression analysis of variables potentially associated with increased risk of disease progression in 44 dogs with stage IV cutaneous mast cell tumors.

Variable	HR	95% CI	P
Tumor diameter > 3 cm at presentation	3.30	1.39-7.82	0.007*
More than 2 metastatic sites	2.91	1.18-7.18	0.021*
Substage b	1.08	0.40-2.50	0.801
Measurable primary tumor at diagnosis of stage IV disease	2.41	1.08-5.40	0.034*

* = significant.

Table 4. Multivariate Cox regression analysis of variables potentially associated with increased risk of tumor-related death in 44 dogs with stage IV cutaneous mast cell tumors.

Variable	HR	95% CI	P
Tumor diameter > 3 cm at presentation	1.77	0.77-4.09	0.182
Node metastasis	786953.16	0.00- 4.58E238	0.960
More than 2 metastatic sites	1.31	0.53-3.24	0.563
Bone marrow infiltration	3.30	1.16-9.42	0.026*
Substage b	1.32	0.57-3.02	0.518
Lack of local tumor control	4.28	1.41-13.01	0.010*
Lack of distant tumor control	1.14	0.47-2.78	0.776

* = significant.